Replies to post #87459 on Biotech Values

[tony111]

There are two other rampalogs that are already on the market. From the research that I have done Rida does not have any safety advantage over the other two. Therefore, I am not sure why would someone think Rida is best in class. Also I would think a dual mTORC inhibitor combined with IGF-1R inhibitor would potentially give a better response.